Acoustic Neuroma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Acoustic Neuroma Market Outlook

Thelansis’s “Acoustic Neuroma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acoustic Neuroma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acoustic Neuroma Overview

Acoustic neuroma, also referred to as vestibular schwannoma (VS), acoustic neurinoma, vestibular neuroma or acoustic neurofibroma, is a benign, slow-growing neoplasm arising from the sheath of the vestibular branch of the vestibulocochlear nerve. It is the most common tumor of the cerebellopontine angle and the internal auditory canal. Its symptoms include hearing loss in one ear, noise in the ear, balance problems, and vertigo. The Schwann cells that invest the vestibular portion of the vestibulocochlear nerve cause the vast majority of cases, with less than 5% arising from the cochlear nerve. With roughly equal frequency, the superior and inferior vestibular nerves appear to be the nerves of origin. It is classified into two types: sporadic acoustic neuroma, unilateral and genetic, and bilateral acoustic neuroma. Sporadic, unilateral acoustic neuromas are tumors on one side of the body in 95% of patients. They are caused by sporadic (sudden) nonhereditary mutations and occur most commonly in people between the ages of 30 and 60. On the other hand, genetic, bilateral acoustic neuromas occur in people with the genetic disorder neurofibromatosis type 2, caused by a mutation in chromosome 22 that affects the gene responsible for the production of Schwann cells. These patients frequently have other schwannoma-like tumors throughout their bodies, and their treatment may differ from unilateral tumors. The diagnosis is made with a contrast magnetic resonance imaging (MRI) or computed tomogram scan; audiometric tests are needed if the hearing impairment is present.

• The incidence of Acoustic neuroma ranges from 1 to 2 cases per 100,000 person-years in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: